Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-401, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Plakophilin-2 (PKP2) Transgene, in Adults With PKP2 Mutation-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

NCT06228924 is registered in ClinicalTrials.gov with Tenaya Therapeutics as lead sponsor.

NCT NCT06228924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06228924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-401, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Plakophilin-2 (PKP2) Transgene, in Adults With PKP2 Mutation-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Lead sponsor
Tenaya Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
March 26, 2024
Completion date
October 1, 2029
Enrollment
15 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

arrhythmogenic right ventricular cardiomyopathy